175 related articles for article (PubMed ID: 20397824)
1. Aptamers: the emerging class of future anticoagulation for vascular disease.
Kuliczkowski W; Floyd J; Malinin A; Serebruany V
Expert Rev Cardiovasc Ther; 2010 Apr; 8(4):503-7. PubMed ID: 20397824
[TBL] [Abstract][Full Text] [Related]
2. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
[TBL] [Abstract][Full Text] [Related]
3. The potential of aptamers as anticoagulants.
Nimjee SM; Rusconi CP; Harrington RA; Sullenger BA
Trends Cardiovasc Med; 2005 Jan; 15(1):41-5. PubMed ID: 15795162
[TBL] [Abstract][Full Text] [Related]
4. Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
Bompiani KM; Woodruff RS; Becker RC; Nimjee SM; Sullenger BA
Curr Pharm Biotechnol; 2012 Aug; 13(10):1924-34. PubMed ID: 22352726
[TBL] [Abstract][Full Text] [Related]
5. Factor IXa inhibitors as novel anticoagulants.
Howard EL; Becker KC; Rusconi CP; Becker RC
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):722-7. PubMed ID: 17272750
[TBL] [Abstract][Full Text] [Related]
6. Antidote-mediated control of an anticoagulant aptamer in vivo.
Rusconi CP; Roberts JD; Pitoc GA; Nimjee SM; White RR; Quick G; Scardino E; Fay WP; Sullenger BA
Nat Biotechnol; 2004 Nov; 22(11):1423-8. PubMed ID: 15502817
[TBL] [Abstract][Full Text] [Related]
7. Aptamers: from bench side research towards patented molecules with therapeutic applications.
Majumder P; Gomes KN; Ulrich H
Expert Opin Ther Pat; 2009 Nov; 19(11):1603-13. PubMed ID: 19852719
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology and aptamers: applications in drug delivery.
Levy-Nissenbaum E; Radovic-Moreno AF; Wang AZ; Langer R; Farokhzad OC
Trends Biotechnol; 2008 Aug; 26(8):442-9. PubMed ID: 18571753
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-based modulation of blood coagulation.
Mayer G; Rohrbach F; Pötzsch B; Müller J
Hamostaseologie; 2011 Nov; 31(4):258-63. PubMed ID: 22065102
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase.
Müller J; Freitag D; Mayer G; Pötzsch B
J Thromb Haemost; 2008 Dec; 6(12):2105-12. PubMed ID: 18826387
[TBL] [Abstract][Full Text] [Related]
12. Aptamers as candidate therapeutics for cardiovascular indications.
Keefe AD; Schaub RG
Curr Opin Pharmacol; 2008 Apr; 8(2):147-52. PubMed ID: 18222730
[TBL] [Abstract][Full Text] [Related]
13. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent.
Cosmi B
Curr Opin Mol Ther; 2009 Jun; 11(3):322-8. PubMed ID: 19479665
[TBL] [Abstract][Full Text] [Related]
14. Aptamers--basic research, drug development, and clinical applications.
Proske D; Blank M; Buhmann R; Resch A
Appl Microbiol Biotechnol; 2005 Dec; 69(4):367-74. PubMed ID: 16283295
[TBL] [Abstract][Full Text] [Related]
15. Anti-coagulant aptamers.
Gopinath SC
Thromb Res; 2008; 122(6):838-47. PubMed ID: 18055002
[TBL] [Abstract][Full Text] [Related]
16. RNA aptamers as reversible antagonists of coagulation factor IXa.
Rusconi CP; Scardino E; Layzer J; Pitoc GA; Ortel TL; Monroe D; Sullenger BA
Nature; 2002 Sep; 419(6902):90-4. PubMed ID: 12214238
[TBL] [Abstract][Full Text] [Related]
17. The development and testing of aptamers for cancer.
Barbas AS; White RR
Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
[TBL] [Abstract][Full Text] [Related]
18. Regulatable aptamers in medicine: focus on antithrombotic strategies.
Potti A; Rusconi CP; Sullenger BA; Ortel TL
Expert Opin Biol Ther; 2004 Oct; 4(10):1641-7. PubMed ID: 15461575
[TBL] [Abstract][Full Text] [Related]
19. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis.
Becker RC; Chan MY
Curr Opin Mol Ther; 2009 Dec; 11(6):707-15. PubMed ID: 20072947
[TBL] [Abstract][Full Text] [Related]
20. Emerging anticoagulants: mechanism of action and future potential.
Klement P; Rak J
Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
